N/A N=100 The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
Diabetes Type 2
Primary: Flow Mediated Vasodilation — 4.8; 4.4 percentage change over baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=70 Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities — 0.0; 0.0; 0.0; 0.0 percentage of…
Phase 3 N=70 Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
Major Depressive Disorder (MDD)
Primary: Change in Total MADRS Scores From Baseline to Week 8 — -24.95; -18.95; -23.89 units on a scale
N/A N=29 Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
ADHD
Primary: Weight Change — 0.37; -0.04 kilograms
Phase 3 N=3,397 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Phase 2 N=38 Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation
Head Lice Infestation
Primary: Number of the Subjects With AEs. — 8 participants
Phase 3 N=3,731 Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Metabolism and Nutrition Disorder · Obesity
Primary: Change From Baseline in Fasting Body Weight — -7.98; -2.62 percent change — p=<0.0001
N/A N=47,208 Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
Human Papilloma Virus (HPV)
Primary: Percentage of Participants With a Diagnosis of ≥ CIN2 — 14.0; 0.8 Percentage of participants
Phase 3 N=155 Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Pain
Primary: The Number of Participants With Adverse Events as a Measure of Safety. — 5; 22; 13; 60 participants
Phase 2 N=90 A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Percentage of Participants With Disease Progression or Death — 61.1 percentage of participants
Phase 4 N=54 A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
Rheumatoid Arthritis
Primary: Percent Change From Baseline to Week 12 in Synovitis Measured by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic…
Phase 2 N=15 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Number of Participants With Dose-limiting Toxicity (Phase I) — 0; 0; 0; 1 participants
Phase 3 N=120 The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis
Dental Plaque · Gingivitis
Primary: Dental Plaque Scores — 3.33; 3.19; 3.31 units on a scale — p=0.434
N/A N=26 Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Kidney Cancer
Primary: Safety of Sunitinib Malate (SM) — .350 proportion of participants
Phase 2 N=14 Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Area Under the Postprandial Curve (AUC) for Rate of Appearance (Ra) of Exogenous Glucose — 101.97; 93.89; 63.84; 97.76 (umol/kg FFM/min)*hr